News
Company news and announcements
Updates on our clinical trials, regulatory milestones, and company growth. Coverage below is translated from Korean-language press; each link opens the original Korean article.
Beyond Medicine unveils Clickless at VivaTech 2026 in Paris, targeting the European digital healthcare market
At Europe's largest tech exhibition, Beyondmedicine showcased Clickless and its data-driven approach to TMD care, pointing to adoption interest from roughly 80 Korean dental clinics and clinical results showing more than a 3x reduction in pain.
Read more80 dental clinics move to adopt Clickless at SIDEX 2026
At Korea's largest dental industry exhibition, Beyondmedicine confirmed prescribing interest from roughly 80 clinics, bringing its national dental network to more than 1,300 clinics ahead of Clickless's mid-June prescription launch.
Read more (Korean source)Beyondmedicine presents Clickless clinical results at US IADR conference
At the International Association for Dental Research conference in San Diego, Beyondmedicine shared trial results showing 96%+ symptom improvement for Clickless, which uses daily behavior-data monitoring to address TMD's roughly 50% relapse rate.
Read more (Korean source)Clickless becomes the world's first authorized digital therapeutic for TMD
In a KIMES 2026 interview, CEO Daehyun Kim discussed Clickless's regulatory approval from Korea's Ministry of Food and Drug Safety — a world first for temporomandibular disorder — and plans to begin hospital prescriptions while pursuing FDA clearance in the US.
Read more (Korean source)Beyond Medicine showcases Clickless at CES 2026
At CES 2026 Unveiled, Beyondmedicine presented Clickless's facial-movement-analysis and CBT-based approach to TMD, citing a 96% efficacy rate from a confirmatory trial at Hallym University Hospital. CEO Dae-hyun Kim outlined plans to pursue FDA Breakthrough Device Designation and U.S. university hospital partnerships.
Read moreCTV News: What to expect from CES 2026
In its CES 2026 preview, CTV News named Beyondmedicine's prescription app for jaw disorders among the AI-driven healthcare products expected on the show floor.
Read moreClickless receives Class 2 medical device approval from Korea's MFDS
Beyondmedicine announced that Clickless obtained Class 2 digital medical device approval — the first such approval worldwide for a TMD-focused digital therapeutic — combining CBT-based behavior correction, guided relaxation, jaw-muscle rehabilitation, and data-driven monitoring in a six-week program.
Read more (Korean source)Multicenter trial results for Clickless published in JMIR
A randomized, sham-controlled trial of 102 TMD patients across two Hallym University hospitals found the Clickless group's pain scores fell roughly 3x faster than the sham group's, with jaw-opening and oral-habit measures improving 3–5x.
Read more (Korean source)Clickless DTx designated Korea's first innovative medical device in dentistry
Korea's Ministry of Food and Drug Safety designated Clickless DTx as Innovative Medical Device No. 82 — the first such designation in the dental field, recognizing its AI-driven, behavior-based approach to TMD care.
Read more (Korean source)Beyond Medicine showcases Clickless DTx at KIMES 2025 INSPIRE Zone
At Korea's largest medical device exhibition, Beyondmedicine presented Clickless DTx's smartphone-camera jaw-movement analysis, alongside plans to expand into the US, European, and Japanese markets.
Read moreBeyondmedicine raises pre-Series A round from TA Advisors
The round will fund the confirmatory clinical trial required for Clickless's approval from Korea's Ministry of Food and Drug Safety, as Beyondmedicine continues development of the world's first digital therapeutic for TMD.
Read more (Korean source)